{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:14:59Z","timestamp":1777918499406,"version":"3.51.4"},"reference-count":12,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Papillary renal cell carcinoma (pRCC) represents the second most common histologic subtype of renal cell carcinoma and comprises 2 subtypes. Prognosis for type 2 is associated with poor clinical outcome. Current guidelines are based on phase II trials, phase III trials in patients with clear cell histology, or retrospective data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description:<\/jats:title>\n                    <jats:p>To our knowledge, we describe for the first time a case of a patient with heavily pretreated metastatic pRCC who benefited from the combination of lenvatinib plus everolimus for more than 2 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>According to immunohistologic and biological findings in our patient both on primary tumor and liver metastasis, we hypothesize that selected patients with metastatic pRCC, progressed to standard\/available treatments (including angiogenic drugs, mTOR inhibitors, and immunotherapy) and dissociated response to everolimus, could benefit from adding lenvatinib to everolimus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0300891620924472","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T05:23:06Z","timestamp":1590556986000},"page":"NP79-NP83","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report"],"prefix":"10.1177","volume":"106","author":[{"given":"Teresa","family":"Zielli","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Gnetti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Pathology Unit, University Hospital of Parma, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-0226","authenticated-orcid":false,"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"bibr1-0300891620924472","unstructured":"European Society for Medical Oncology. Renal Cell Carcinoma: ESMO Clinical Practice Guidelines, https:\/\/www.esmo.org\/Guidelines\/Genitourinary-Cancers\/Renal-Cell-Carcinoma (accessed 1 February 2020)."},{"key":"bibr2-0300891620924472","doi-asserted-by":"publisher","DOI":"10.1177\/0300891619853392"},{"key":"bibr3-0300891620924472","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.123"},{"key":"bibr4-0300891620924472","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds582"},{"key":"bibr5-0300891620924472","doi-asserted-by":"publisher","DOI":"10.1159\/000350005"},{"key":"bibr6-0300891620924472","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00290-9"},{"key":"bibr7-0300891620924472","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S126910"},{"key":"bibr8-0300891620924472","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv170"},{"key":"bibr9-0300891620924472","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1200\/JCO.2015.60.9727","volume":"33","author":"Flaherty KT","year":"2015","journal-title":"J Clin Oncol"},{"key":"bibr10-0300891620924472","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.5305"},{"key":"bibr11-0300891620924472","first-page":"25","author":"Suyama K","year":"2018","journal-title":"Cancer Control"},{"key":"bibr12-0300891620924472","first-page":"9","author":"Mennitto A","year":"2020","journal-title":"J Clin Med"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300891620924472","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0300891620924472","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0300891620924472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:40:32Z","timestamp":1777660832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0300891620924472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1177\/0300891620924472"],"URL":"https:\/\/doi.org\/10.1177\/0300891620924472","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]}}}